Loading...

BioSpecifics Technologies

BST:1B3
Snowflake Description

Flawless balance sheet with solid track record.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1B3
BST
$460M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
1B3 Share Price and Events
7 Day Returns
-9.4%
BST:1B3
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
56.3%
BST:1B3
-10.2%
DE Biotechs
-6%
DE Market
1B3 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioSpecifics Technologies (1B3) -9.4% -8% -6.6% 56.3% 67.9% 210.4%
DE Biotechs -2.4% 1.8% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.2% 7.4% -6% 10.1% 15.4%
1 Year Return vs Industry and Market
  • 1B3 outperformed the Biotechs industry which returned -10.2% over the past year.
  • 1B3 outperformed the Market in Germany which returned -6% over the past year.
Price Volatility
1B3
Industry
5yr Volatility vs Market
Related Companies

Value

 Is BioSpecifics Technologies undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of BioSpecifics Technologies to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for BioSpecifics Technologies.

BST:1B3 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for BST:1B3
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for BST:1B3 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for BioSpecifics Technologies is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

BST:1B3 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.98%)
2019 18.29 Est @ 3.13% 16.94
2020 18.70 Est @ 2.26% 16.04
2021 19.01 Est @ 1.65% 15.10
2022 19.24 Est @ 1.22% 14.16
2023 19.42 Est @ 0.93% 13.23
2024 19.56 Est @ 0.72% 12.34
2025 19.67 Est @ 0.57% 11.50
2026 19.76 Est @ 0.47% 10.70
2027 19.84 Est @ 0.4% 9.95
2028 19.91 Est @ 0.35% 9.24
Present value of next 10 years cash flows $129.18
BST:1B3 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $19.91 × (1 + 0.23%) ÷ (7.98% – 0.23%)
$257.54
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $257.54 ÷ (1 + 7.98%)10
$119.56
BST:1B3 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $129.18 + $119.56
$248.74
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $248.74 / 7.29
$34.14
BST:1B3 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in BST:1B3 represents 0.8465x of NasdaqGM:BSTC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.8465x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 34.14 x 0.8465
€28.90
Value per share (EUR) From above. €28.90
Current discount Discount to share price of €53.49
= -1 x (€53.49 - €28.90) / €28.90
-85.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of BioSpecifics Technologies is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioSpecifics Technologies's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioSpecifics Technologies's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:1B3 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $2.77
NasdaqGM:BSTC Share Price ** NasdaqGM (2019-04-18) in USD $63.19
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioSpecifics Technologies.

BST:1B3 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:BSTC Share Price ÷ EPS (both in USD)

= 63.19 ÷ 2.77

22.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioSpecifics Technologies is overvalued based on earnings compared to the Europe Biotechs industry average.
  • BioSpecifics Technologies is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does BioSpecifics Technologies's expected growth come at a high price?
Raw Data
BST:1B3 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 22.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
12.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioSpecifics Technologies, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioSpecifics Technologies's assets?
Raw Data
BST:1B3 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $13.41
NasdaqGM:BSTC Share Price * NasdaqGM (2019-04-18) in USD $63.19
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.84x
BST:1B3 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:BSTC Share Price ÷ Book Value per Share (both in USD)

= 63.19 ÷ 13.41

4.71x

* Primary Listing of BioSpecifics Technologies.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioSpecifics Technologies is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess BioSpecifics Technologies's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. BioSpecifics Technologies has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is BioSpecifics Technologies expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

  • No analysts cover BioSpecifics Technologies, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioSpecifics Technologies expected to grow at an attractive rate?
  • BioSpecifics Technologies's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • BioSpecifics Technologies's earnings growth is expected to exceed the Germany market average.
  • Unable to compare BioSpecifics Technologies's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BST:1B3 Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:1B3 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 12.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:1B3 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:1B3 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 37 1
BST:1B3 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 33 18 20
2018-09-30 30 16 17
2018-06-30 27 15 14
2018-03-31 27 9 12
2017-12-31 27 13 11
2017-09-30 27 11 12
2017-06-30 28 13 12
2017-03-31 27 12 12
2016-12-31 26 16 11
2016-09-30 26 19 11
2016-06-30 25 16 11
2016-03-31 24 16 10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioSpecifics Technologies's earnings are expected to grow by 12.6% yearly, however this is not considered high growth (20% yearly).
  • Unable to determine if BioSpecifics Technologies is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:1B3 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BioSpecifics Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:1B3 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31
BST:1B3 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 2.77
2018-09-30 2.29
2018-06-30 1.90
2018-03-31 1.67
2017-12-31 1.58
2017-09-30 1.62
2017-06-30 1.67
2017-03-31 1.67
2016-12-31 1.61
2016-09-30 1.59
2016-06-30 1.57
2016-03-31 1.47

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioSpecifics Technologies will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioSpecifics Technologies's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioSpecifics Technologies has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has BioSpecifics Technologies performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioSpecifics Technologies's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioSpecifics Technologies has delivered over 20% year on year earnings growth in the past 5 years.
  • BioSpecifics Technologies's 1-year earnings growth exceeds its 5-year average (77% vs 25.2%)
  • BioSpecifics Technologies's earnings growth has exceeded the Europe Biotechs industry average in the past year (77% vs 18.2%).
Earnings and Revenue History
BioSpecifics Technologies's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioSpecifics Technologies Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:1B3 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 32.96 20.05 8.81 0.76
2018-09-30 29.81 16.51 7.97 0.84
2018-06-30 27.40 13.64 7.86 1.04
2018-03-31 26.84 11.96 8.19 1.16
2017-12-31 27.44 11.33 8.54 1.22
2017-09-30 27.36 11.60 8.90 1.27
2017-06-30 27.73 11.94 8.57 1.23
2017-03-31 27.37 11.89 8.16 1.33
2016-12-31 26.25 11.37 7.90 1.33
2016-09-30 25.77 11.11 7.87 1.29
2016-06-30 25.18 10.93 7.74 1.23
2016-03-31 23.71 10.12 7.63 1.04
2015-12-31 22.75 9.62 7.27 1.03
2015-09-30 21.26 8.88 6.73 1.11
2015-06-30 18.97 7.40 6.68 1.09
2015-03-31 16.89 6.22 6.37 1.12
2014-12-31 14.04 4.65 5.81 1.26
2014-09-30 13.47 4.45 5.51 1.28
2014-06-30 12.62 4.24 4.92 1.39
2014-03-31 13.24 4.69 4.67 1.57
2013-12-31 14.43 5.29 5.04 1.48
2013-09-30 13.90 4.66 5.08 1.41
2013-06-30 13.21 3.95 5.39 1.36
2013-03-31 12.54 3.59 5.30 1.30
2012-12-31 11.15 2.98 4.77 1.25
2012-09-30 10.25 1.95 4.67 1.21
2012-06-30 9.72 1.75 4.54 1.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • BioSpecifics Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • BioSpecifics Technologies used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • BioSpecifics Technologies's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess BioSpecifics Technologies's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioSpecifics Technologies has a total score of 5/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is BioSpecifics Technologies's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioSpecifics Technologies's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioSpecifics Technologies is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • BioSpecifics Technologies has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of BioSpecifics Technologies's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • BioSpecifics Technologies has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioSpecifics Technologies Company Filings, last reported 3 months ago.

BST:1B3 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 97.59 0.00 80.88
2018-09-30 91.74 0.00 71.81
2018-06-30 86.94 0.00 66.55
2018-03-31 81.84 0.00 61.31
2017-12-31 67.52 0.00 59.31
2017-09-30 64.71 0.00 54.59
2017-06-30 62.10 0.00 51.15
2017-03-31 59.70 0.00 47.87
2016-12-31 56.28 0.00 49.02
2016-09-30 53.22 0.00 49.82
2016-06-30 49.91 0.00 43.57
2016-03-31 47.60 0.00 41.79
2015-12-31 44.81 0.00 33.49
2015-09-30 42.11 0.00 30.93
2015-06-30 37.27 0.00 27.79
2015-03-31 33.67 0.00 23.74
2014-12-31 30.26 0.00 20.71
2014-09-30 26.01 0.00 17.51
2014-06-30 24.36 0.00 16.63
2014-03-31 23.48 0.00 16.91
2013-12-31 22.33 0.00 12.59
2013-09-30 20.45 0.00 11.33
2013-06-30 19.55 0.00 11.98
2013-03-31 18.63 0.00 12.21
2012-12-31 17.46 0.00 8.50
2012-09-30 16.70 0.00 9.01
2012-06-30 16.15 0.00 8.79
  • BioSpecifics Technologies has no debt.
  • BioSpecifics Technologies has not taken on any debt in the past 5 years.
  • BioSpecifics Technologies has no debt, it does not need to be covered by operating cash flow.
  • BioSpecifics Technologies has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess BioSpecifics Technologies's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioSpecifics Technologies has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is BioSpecifics Technologies's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioSpecifics Technologies dividends.
If you bought €2,000 of BioSpecifics Technologies shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioSpecifics Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioSpecifics Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:1B3 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:1B3 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioSpecifics Technologies has not reported any payouts.
  • Unable to verify if BioSpecifics Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioSpecifics Technologies's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioSpecifics Technologies has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioSpecifics Technologies's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioSpecifics Technologies afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioSpecifics Technologies has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of BioSpecifics Technologies's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ronald Law
AGE 65
TENURE AS CEO 0 years
CEO Bio

Dr. Ronald Law, Ph.D., J.D. has been Principal Executive Officer at BioSpecifics Technologies Corp. since April 1, 2019 and served as its Senior Vice President of Business Development since November 15, 2018 until April 1, 2019. Dr. Law had been consulting for BioSpecifics since July 15, 2018. He was Chief Strategy Officer of Oramed Pharmaceuticals Inc. since March 21, 2017 to November 2018. Dr. Law has over 25 years of academic and pharmaceutical industry experience in diabetes, cardiovascular disease and obesity. During his industry career at Takeda Pharmaceuticals, Dr. Law served in a variety of leadership and strategic roles spanning US Medical Affairs, Global Medical Affairs, Corporate Strategic Planning, Global Scientific Affairs and Intelligence and R&D External Innovation. Prior to that, he was a scientific consultant in oncology at Third Coast Therapeutics, a diabetes consultant at Doctor Evidence and a business development consultant at PharmaIN Corporation. He also held several leadership and strategic roles at Takeda Pharmaceuticals International, spanning U.S. Medical Affairs, Global Medical Affairs, Corporate Strategic Planning, Global Scientific Affairs and Intelligence, and R&D External Innovation. Prior to joining Takeda, Dr. Law was an Associate Professor of Medicine in the Endocrinology Division, UCLA School of Medicine. He is a member of the American Diabetes Association and the American Heart Association. He holds a Ph.D. in Molecular Biology from University of California at Los Angeles, a J.D. from the Whittier College School of Law and both an M.S. and B.S. in Biological Sciences from the University of Illinois at Chicago.

CEO Compensation
  • Insufficient data for Ronald to compare compensation growth.
  • Insufficient data for Ronald to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Ronald Law

TITLE
Interim Principal Executive Officer
AGE
65

Patrick Caldwell

TITLE
Interim Principal Financial Officer
AGE
56

Carl Valenstein

TITLE
Corporate Secretary
Board of Directors Tenure

Average tenure and age of the BioSpecifics Technologies board of directors in years:

11.8
Average Tenure
72.5
Average Age
  • The average tenure for the BioSpecifics Technologies board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Paul Gitman

TITLE
Independent Director
COMPENSATION
$65K
AGE
77
TENURE
29.3 yrs

Michael Schamroth

TITLE
Independent Director
COMPENSATION
$65K
AGE
78
TENURE
14.9 yrs

Jyrki Mattila

TITLE
Independent Director
COMPENSATION
$65K
AGE
63
TENURE
4 yrs

Toby Wegman

TITLE
Director
COMPENSATION
$22K
AGE
83
TENURE
11.8 yrs

Mark Wegman

TITLE
Director
COMPENSATION
$65K
AGE
68
TENURE
11.8 yrs

Jenn Chao

TITLE
Independent Director
COMPENSATION
$65K
AGE
48
TENURE
4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
12. Sep 18 Sell Mark Wegman Individual 10. Sep 18 11. Sep 18 -6,500 €50.61 €-322,605
07. Sep 18 Sell Paul Gitman Individual 07. Sep 18 07. Sep 18 -1,000 €49.78 €-49,775
29. Aug 18 Sell Paul Gitman Individual 27. Aug 18 29. Aug 18 -19,000 €42.85 €-807,751
29. Aug 18 Sell Paul Gitman Individual 23. Aug 18 24. Aug 18 -11,825 €44.12 €-520,712
24. Aug 18 Sell Mark Wegman Individual 22. Aug 18 23. Aug 18 -8,500 €45.54 €-386,486
17. Aug 18 Sell Thomas Wegman Individual 18. May 16 17. Aug 18 -78,797 €45.47 €-2,879,229
16. Aug 18 Sell Thomas Wegman Individual 14. Aug 18 15. Aug 18 -23,908 €45.23 €-1,072,947
X
Management checks
We assess BioSpecifics Technologies's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioSpecifics Technologies has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX or Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, and human lipoma, as well as uterine fibroids. In addition, the company engages in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. BioSpecifics Technologies Corp. has a development and license agreement with Endo Global Ventures. The company was founded in 1957 and is headquartered in Lynbrook, New York.

Details
Name: BioSpecifics Technologies Corp.
1B3
Exchange: BST
Founded: 1957
$409,440,442
7,286,902
Website: http://www.biospecifics.com
Address: BioSpecifics Technologies Corp.
35 Wilbur Street,
Lynbrook,
New York, 11563,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM BSTC Common Stock Nasdaq Global Market US USD 14. Nov 1991
BST 1B3 Common Stock Boerse-Stuttgart DE EUR 14. Nov 1991
Number of employees
Current staff
Staff numbers
6
BioSpecifics Technologies employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/20 21:39
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/03
Last earnings filing: 2019/04/02
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.